BioMarin Pharma's (BMRN) Q2 Revenue Tops Views
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.61 +1.68%
EPS Growth %: -34.0%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -34.0%
Financial Fact:
NET INCOME (LOSS) PER SHARE, BASIC: -0.26
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($2.61), may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $300.1 million versus the consensus estimate of $278.16 million.
GUIDANCE:
BioMarin Pharma sees FY2016 revenue of $1.1-1.15 billion, versus prior guidance of $1.05-1.1 billion and the consensus of $1.09 billion.
| Item | ||||
| Provided April 28, 2016 | Updated August 4, 2016 | |||
| Total BioMarin Revenues | $1,050 to $1,100 | $1,100 to $1,150 | ||
| Vimizim Net Product Revenue | $315 to $340 | $340 to $360 | ||
| Naglazyme Net Product Revenue | $290 to $320 | Unchanged | ||
| Kuvan Net Product Revenue | $320 to $350 | $340 to $360 |
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alphabet slides over 6% as AI brain drain and SpaceX slump converge
- Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
